AbCellera Biologics Inc.

AbCellera Biologics Inc. is a clinical-stage biotechnology company specializing in the discovery and development of first-in-class antibody medicines for indications with high unmet medical need. The company has evolved its strategy from primarily a partnership model to building its own internal pipeline of AbCellera-owned drug assets. The therapeutic antibody market is substantial, with global sales reaching approximately $300 billion ¹ in 2025, and is projected to grow to over $500 billion ² by 2030, representing a five-year compound annual growth rate (CAGR) of over 10% ³. In 2025, antibody medicines accounted for 5 ⁴ out of the world’s 10 ⁵ top-selling pharmaceutical products, with around 50 ⁶ achieving blockbuster status (annual sales exceeding $1 billion ⁷).

The company's core business model involves leveraging its proprietary, vertically-integrated antibody drug platform to discover and develop antibody drug candidates. Historically, this involved partnering with biopharmaceutical and biotechnology companies, where AbCellera would deliver optimized antibodies for further development. These partnership agreements typically included near-term payments for access, research, and intellectual property rights, downstream clinical and commercial milestone payments, and royalties on net sales of drugs. The majority of the value from these deals is associated with downstream participation. More recently, AbCellera has shifted its focus to developing its own internal pipeline of drug assets, aiming to generate revenue from out-licensing programs and milestone payments and royalties in the longer term.

AbCellera's pipeline includes two drug candidates in clinical development and two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA))-enabling activities, alongside more than 20 ⁸ active discovery programs. ABCL635 is a potential first-in-class non-hormonal medicine for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, targeting the Neurokinin-3 Receptor (NK3R), a G protein-coupled receptor (GPCR). It is currently in a Phase 1/2 clinical trial in Canada, with topline data anticipated in Q3 2026 ⁹. ABCL575 is a potential best-in-class medicine for atopic dermatitis and other inflammation and immunology (I&I) conditions, targeting OX40 Ligand (OX40L). It is in a Phase 1 clinical trial in Canada, with topline data anticipated in Q4 2026 ¹⁰. ABCL688 is a potential first-in-class antibody medicine for autoimmune conditions, targeting an undisclosed GPCR or Ion Channel, and entered IND/CTA-enabling activities in Q2 2025 ¹¹. ABCL386 is a potential first-in-class antibody medicine for oncology, targeting an undisclosed target, and is also in IND/CTA-enabling activities. Phase 1/2 clinical trials for both ABCL688 and ABCL386 are anticipated to initiate in 2027 ¹².

For the fiscal year ended December 31, 2025, AbCellera reported total revenue of $75.128 million ¹³, a significant increase from $28.833 million ¹⁴ in 2024. This increase was primarily driven by $10.8 million ¹⁵ in licensing revenue and a $36.0 million ¹⁶ payment from a patent litigation settlement. Research fees increased by $0.924 million ¹⁷, or 4% ¹⁸, to $27.208 million ¹⁹ in 2025 from $26.284 million ²⁰ in 2024. Milestone payments decreased by $0.500 million ²¹, or (33)% ²², to $1.000 million ²³ in 2025 from $1.500 million ²⁴ in 2024. Licensing and royalty revenue saw a substantial increase of $45.871 million ²⁵, or 4373% ²⁶, reaching $46.920 million ²⁷ in 2025 from $1.049 million ²⁸ in 2024.

Total operating expenses decreased by $51.368 million ²⁹, or (14.9)% ³⁰, to $292.231 million ³¹ in 2025 from $343.599 million ³² in 2024. Research and development expenses, exclusive of depreciation, amortization, and impairment, increased by $19.570 million ³³, or 12% ³⁴, to $186.829 million ³⁵ in 2025 from $167.259 million ³⁶ in 2024. Sales, general, and administrative expenses decreased by $2.259 million ³⁷, or (3)% ³⁸, to $83.231 million ³⁹ in 2025 from $85.490 million ⁴⁰ in 2024. Depreciation, amortization, and impairment expenses significantly decreased by $68.679 million ⁴¹, or (76)% ⁴², to $22.171 million ⁴³ in 2025 from $90.850 million ⁴⁴ in 2024, primarily due to full impairment charges recognized in 2024 for in-process research and development (IPR&D) assets from the Trianni and TetraGenetics acquisitions. The company reported a net loss of $146.412 million ⁴⁵ in 2025, an improvement from a net loss of $162.857 million ⁴⁶ in 2024. Basic and diluted EPS were both $(0.49) ⁴⁷ in 2025, compared to $(0.55) ⁴⁸ in 2024. As of December 31, 2025, cash and cash equivalents were $128.513 million ⁴⁹, and marketable securities were $405.313 million ⁵⁰, totaling $533.826 million ⁵¹ in available liquidity. Total assets were $1,356.950 million ⁵², and total shareholders' equity was $966.904 million ⁵³.

During 2025, AbCellera achieved several significant operational milestones. The company initiated clinical trials for its first two internal drug candidates, ABCL635 and ABCL575, in Canada. ABCL635, for moderate-to-severe VMS, entered a Phase 1/2 trial, and ABCL575, for atopic dermatitis, entered a Phase 1 trial. Two additional development candidates, ABCL688 and ABCL386, were nominated and entered IND/CTA-enabling activities. A major infrastructure investment was completed with the opening of its 130,000-square-foot ⁵⁴ clinical manufacturing facility in Vancouver, which is expected to enhance supply chain control, flexibility, timelines, and intellectual property protection. The company also settled patent infringement litigation with Bruker Cellular Analysis in December 2025, resulting in an upfront payment of $36.0 million ⁵⁵ and future royalty payments on sales of Bruker's Beacon Optofluidic platform products.

AbCellera anticipates generating losses and negative operating cash flow in the near-to-medium term, ahead of revenues from out-licensing programs, milestone payments, and royalties in the longer term. The company believes it has approximately $700 million ⁵⁶ in available liquidity as of December 31, 2025, which is expected to fund operations beyond the next three years. The company does not anticipate the need for additional external funding over at least the next thirty-six (36) months ⁵⁷ following the date of this report, based on its current business plan and available liquidity from existing cash, cash equivalents, marketable securities, loan receivables, and government contributions.

A key growth area for AbCellera is the advancement of its internal pipeline of drug candidates. ABCL635, a potential first-in-class non-hormonal medicine for moderate-to-severe VMS, is currently in a Phase 1/2 clinical trial, with topline data anticipated in Q3 2026 ⁵⁸. Following this, the company foresees initiating Phase 2 studies for ABCL635 in oncology-related VMS in 2027 ⁵⁹. ABCL575, a potential best-in-class medicine for atopic dermatitis, is in a Phase 1 clinical trial, with topline data anticipated in Q4 2026 ⁶⁰. However, the company does not anticipate developing ABCL575 past Phase 1 as a monotherapy, aligning with its focus on first-in-class medicines. Two additional development candidates, ABCL688 for autoimmune conditions and ABCL386 for oncology, are in IND/CTA-enabling activities, with Phase 1/2 clinical trials anticipated to initiate in 2027 ⁶¹. The company also expects to progress additional internal programs into development candidate selection for IND-enabling activities in the near-to-medium term.

Operationally, AbCellera has substantially completed its platform investments with the opening of its 130,000-square-foot ⁶² clinical manufacturing facility in Vancouver in late 2025. This facility is expected to enable the company to control its supply chain, improve flexibility, accelerate timelines, and better protect its intellectual property, supporting the advancement of antibody drug programs from target selection through to clinical trials, including manufacturing drug substance for early phase trials. The company has now shifted its focus from building capabilities to building its pipeline, which is expected to result in a reduction in investing cash outflows. The company also intends to optimize its long-term office-lease arrangements and plans to assign or fully sublease the 220,000 square feet ⁶³ of additional lab and office space constructed through the Beedie joint venture.

In terms of capital allocation, AbCellera plans to continue significant investments in research and development efforts to expand its capabilities and expertise, and to grow and advance its internal pipeline. This includes ongoing investments in its discovery and development capabilities, including manufacturing, and continued research and development on its pipeline of internal programs. The company has received CAD $475.6 million ($347.9 million) ⁶⁴ in non-dilutive government financing since 2020, including CAD $300 million ($222.3 million) ⁶⁵ from the Governments of Canada and British Columbia in May 2023, to build new capabilities and support the development of up to 17 ⁶⁶ internal programs through Phase 1 clinical trials. The company's strategy emphasizes maximizing long-term value through capital-efficient investments in new antibody drug candidates, with the largest value tied to their long-term success, often resulting in cash flows further in the future.

The company explicitly flags several structural headwinds and execution risks. Its long-term financial success is increasingly dependent on its ability to successfully transition drug candidates from its discovery platform through clinical development, which requires significant financial investment and carries inherent risks. The strategic pivot from a primarily partnership-focused business to one focused on developing its own internal pipeline requires different capital allocation, operational expertise, and risk management, potentially leading to reduced near-term revenue from partnerships, increased cash costs, and greater exposure to clinical trial outcomes. There is no guarantee that the FDA will accept data from foreign Phase 1/2 trials (such as those for ABCL635 and ABCL575 in Canada) as sufficient to support a U.S. Phase 3 start, potentially requiring additional bridging studies or repeat Phase 1/2 trials in the United States, which would delay timelines. The company also acknowledges that its estimates of market opportunity and forecasts of market growth may prove inaccurate, and even if markets grow as forecasted, its drug candidates may fail to achieve sufficient market acceptance or adoption.

AbCellera faces numerous material risks, including the inherent uncertainty of drug development, which has led to losses in certain years, including $146.4 million ⁶⁷ in 2025, and the expectation of continued losses and negative operating cash flow in the near-to-medium term. The company's commercial success is highly dependent on the quality of its antibody discovery and development capabilities and the successful advancement and market acceptance of its internal programs and partner-developed drugs. Failure to execute its strategic pivot from a partnership model to an internal pipeline focus could adversely impact growth and profitability, potentially leading to reduced near-term partnership revenue, increased cash costs, and greater exposure to clinical trial risks. The development of biological molecules is inherently uncertain, with a high risk of failure at any stage, and there is no assurance that any drug candidates will receive marketing approval or become commercially viable. Delays or failures in clinical trials, including patient enrollment challenges, unforeseen safety issues, or lack of efficacy, could prevent timely regulatory approval and commercialization. The company's reliance on third parties for clinical trial monitoring, support, and manufacturing, as well as the potential for manufacturing difficulties, supply shortages, and price fluctuations from limited or single-source suppliers, poses operational risks. Intellectual property protection is critical, and the inability to obtain, maintain, or enforce patents, or challenges to existing patents (such as the ongoing civil lawsuit with the Estate of John Schrader regarding Canadian patent No. 2,655,511 ⁶⁸), could impair competitive advantage and lead to substantial litigation costs. The company is also exposed to risks from unstable market and economic conditions, including potential impacts on liquidity, credit availability, and the value of its cash and marketable securities, as well as the effects of inflation on operating costs. Regulatory risks are significant, with extensive and evolving government regulations in the U.S., Canada, and other jurisdictions governing drug development, manufacturing, approval, pricing, and commercialization. Changes in healthcare legislation, such as the Inflation Reduction Act of 2022, could impose price controls, reduce reimbursement, and increase compliance burdens. Cybersecurity threats, including attacks on information technology systems, could compromise sensitive data, disrupt operations, and lead to significant financial and legal exposure. Furthermore, the company's international operations expose it to business, regulatory, political, operational, financial, and economic risks, including foreign currency exchange rate fluctuations and compliance with anti-corruption laws like the FCPA and CFPOA.

Management's overall tone emphasizes a strategic pivot towards becoming a clinical-stage biotechnology company focused on developing its own internal pipeline of first-in-class antibody medicines, leveraging its integrated platform built over nearly 15 years with approximately $1 billion ⁶⁹ in investment. They highlight the completion of the 130,000-square-foot ⁷⁰ clinical manufacturing facility in Vancouver as a culmination of platform investments, shifting focus from building capabilities to building the pipeline. Key strategic priorities include advancing the two clinical candidates, ABCL635 and ABCL575, with anticipated topline data readouts in Q3 2026 ⁷¹ and Q4 2026 ⁷² respectively, and progressing ABCL688 and ABCL386 into Phase 1/2 clinical trials in 2027 ⁷³. Management also stresses the importance of capital allocation with a long-term perspective, aiming to maximize value by addressing challenging antibody discovery and development problems and capturing value through downstream stakes in successful drugs, both internally and with partners. They believe the company has sufficient liquidity of approximately $700 million ⁷⁴ to fund operations beyond the next three years and does not anticipate the need for additional external funding over at least the next 36 months ⁷⁵.